# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored ...
Jefferies analyst Maury Raycroft assumes Prime Medicine (NASDAQ:PRME) with a Buy rating and lowers Price Target of $15.
Prime Medicine expects to report initial clinical data from the study in 2025.
Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated, one-time cur...
Wedbush analyst David Nierengarten reiterates Prime Medicine (NASDAQ:PRME) with a Outperform and maintains $12 price target.